meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - colorectal cancer (mCRC)
mCRC - 1st line (L1)
1
mCRC - 2nd line (L2)
3
endometrial cancer
1
esophageal cancer (EC)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus cometinib
Immune checkpoint association
durvalumab plus tremelimumab
versus all
vs non active control
vs BSC
vs placebo
vs VEGF(R) inhibitor
vs regorafenib
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
atezolizumab alone
title
atezolizumab plus cometinib
title
regorafenib
title
IMblaze-370 (A ; all population), 2019 NCT02788279 mCRC - 2nd line (L2) 90/90
IMblaze-370 (AC ; all population), 2019 NCT02788279 mCRC - 2nd line (L2) 183/90
Pathology:
mCRC - 2nd line (L2);
mCRC - 2nd line (L2)
IMblaze-370 (A ; all population), 2019
IMblaze-370 (AC ; all population), 2019
atezolizumab alone
1
T1
atezolizumab plus cometinib
1
T1
regorafenib
0
T0
T0